Maze Therapeutics, Inc. earnings releases MAZE

Annual Quarterly

Maze Therapeutics, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $0 and diluted EPS of -$0.76. It usually reports 37–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 11, 2026
42 days after quarter end
Q2 FY2026
ended Jun 30, 2026
0
-45
-32.8%
-0.76
+1.3%
May 12, 2026
42 days after quarter end
Q1 FY2026
ended Mar 31, 2026
20
-24
+26.2%
-0.45
+60.9%
Nov 6, 2025
37 days after quarter end
Q3 FY2025
ended Sep 30, 2025
—
-30
-0.66
Aug 12, 2025
43 days after quarter end
Q2 FY2025
ended Jun 30, 2025
0
-34
-0.77
May 14, 2025
44 days after quarter end
Q1 FY2025
ended Mar 31, 2025
—
-33
-1.15

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MAZE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
1842295

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.